Zynerba Pharmaceuticals, Inc. (ZYNE)

NASDAQ: ZYNE · IEX Real-Time Price · USD
0.959
-0.029 (-2.96%)
At close: May 20, 2022 4:00 PM
0.941
-0.019 (-1.929%)
After-hours:May 20, 2022 7:40 PM EDT
Market Cap41.83M
Revenue (ttm)n/a
Net Income (ttm)-37.84M
Shares Out43.62M
EPS (ttm)-0.96
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume290,596
Open1.010
Previous Close0.988
Day's Range0.909 - 1.010
52-Week Range0.836 - 6.070
Beta2.11
AnalystsBuy
Price Target7.09 (+639.3%)
Earnings DateMay 18, 2022

About ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is h...

IndustryPharmaceuticals
IPO DateAug 5, 2015
CEOArmando Anido
Employees28
Stock ExchangeNASDAQ
Ticker SymbolZYNE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.09, which is an increase of 639.31% from the latest price.

Price Target
$7.09
(639.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 –

5 days ago - GlobeNewsWire

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragil...

– Data support the long-term safety and effectiveness of Zygel –

1 week ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

1 week ago - GlobeNewsWire

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragil...

DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...

2 weeks ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

1 month ago - GlobeNewsWire

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

1 month ago - GlobeNewsWire

Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit

DEVON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

1 month ago - GlobeNewsWire

Zynerba (ZYNE) Loses 29.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear...

2 months ago - Zacks Investment Research

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) –

2 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syn...

Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval

2 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

Topline data from Phase 2 INSPIRE trial expected mid-year 2022 Topline data from Phase 2 INSPIRE trial expected mid-year 2022

2 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Names New CLO & Corporate Secretary

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal off...

3 months ago - Benzinga

Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal O...

DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

3 months ago - GlobeNewsWire

Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE). The decision was in line with the feedback from the FDA, which ind...

4 months ago - Benzinga

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

– Company plans to focus development of Zygel™ in FXS, ASD and 22q –

4 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

5 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

5 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights

– Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 –

6 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

7 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare ...

DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

7 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conferen...

DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...

7 months ago - GlobeNewsWire

Top Penny Stocks To Buy The Dip According To Analysts In September

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:DRMANMTRVSTM
7 months ago - PennyStocks

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...

8 months ago - GlobeNewsWire

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with  Fragile X Syndrome

8 months ago - GlobeNewsWire

Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment per...

8 months ago - Benzinga